Clinical Trial Update: A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) [Phase 3]

View source ↗

Summary

Phase 3 study of UX003 rhGUS enzyme replacement therapy for MPS type 7 (Sly syndrome) completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Vii
• Sly Syndrome

Drugs mentioned

• UX003 (recombinant human beta-glucuronidase)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: MPS 7, Sly Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2018-02-19